146 related articles for article (PubMed ID: 7963533)
1. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
[TBL] [Abstract][Full Text] [Related]
2. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models.
Tüting T; Gambotto A; Baar J; Davis ID; Storkus WJ; Zavodny PJ; Narula S; Tahara H; Robbins PD; Lotze MT
Gene Ther; 1997 Oct; 4(10):1053-60. PubMed ID: 9415311
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
7. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.
Belardelli F; Ferrantini M; Santini SM; Baccarini S; Proietti E; Colombo MP; Sprent J; Tough DF
Cancer Res; 1998 Dec; 58(24):5795-802. PubMed ID: 9865738
[TBL] [Abstract][Full Text] [Related]
8. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines.
Santodonato L; D'Agostino G; Santini SM; Carlei D; Musiani P; Modesti A; Signorelli P; Belardelli F; Ferrantini M
Gene Ther; 1997 Nov; 4(11):1246-55. PubMed ID: 9425449
[TBL] [Abstract][Full Text] [Related]
9. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
11. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
12. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
Pericle F; Giovarelli M; Colombo MP; Ferrari G; Musiani P; Modesti A; Cavallo F; Di Pierro F; Novelli F; Forni G
J Immunol; 1994 Dec; 153(12):5659-73. PubMed ID: 7989764
[TBL] [Abstract][Full Text] [Related]
13. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
[TBL] [Abstract][Full Text] [Related]
14. Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.
Rozera C; Carlei D; Lollini PL; De Giovanni C; Musiani P; Di Carlo E; Belardelli F; Ferrantini M
Am J Pathol; 1999 Apr; 154(4):1211-22. PubMed ID: 10233859
[TBL] [Abstract][Full Text] [Related]
15. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
Musiani P; Modesti A; Brunetti M; Modica A; Vitullo P; Gulino A; Bosco MC; Colombo MP; Nanni P; Cavallo F
Nat Immun; 1994; 13(2-3):93-101. PubMed ID: 8173240
[TBL] [Abstract][Full Text] [Related]
16. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression.
Esumi N; Hunt B; Itaya T; Frost P
Cancer Res; 1991 Feb; 51(4):1185-9. PubMed ID: 1900037
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
Santodonato L; Ferrantini M; Palombo F; Aurisicchio L; Delmastro P; La Monica N; Di Marco S; Ciliberto G; Du MX; Taylor MW; Belardelli F
Cancer Gene Ther; 2001 Jan; 8(1):63-72. PubMed ID: 11219495
[TBL] [Abstract][Full Text] [Related]
18. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.
Gansbacher B; Bannerji R; Daniels B; Zier K; Cronin K; Gilboa E
Cancer Res; 1990 Dec; 50(24):7820-5. PubMed ID: 2123742
[TBL] [Abstract][Full Text] [Related]
19. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
